OLIGORARE - Stereotactic body radiotherapy in addition to standard of care

Grant Details

Grantee Name: Matthias Guckenberger
Organization: ACF
Country: Belgium

Project Name: OLIGORARE - Stereotactic body radiotherapy in addition to standard of care
Funding Year: 2020
Project period: 5 years

Based upon a strong scientific rationale, this proposal seeks funding to support a randomized phase III clinical trial investigating the addition of stereotactic radiotherapy to the standard of care treatment for patients with oligometastatic rare cancer. To this end, the primary objective of this clinical trial is to assess if the addition of SBRT improves overall survival (OS) as compared to standard of care treatment alone in patients with oligometastatic rare cancers.


Lay Abstract

Metastatic cancer can range from a single metastasis to widely disseminated metastases, making it the leading cause of cancer death. Oligometastases are considered an intermediate state between locoregional cancer and widespread metastases with a limited number of lesions and organs involved. Retrospective studies have shown that aggressive metastasis-directed therapy (surgery or radiation) added to standard of care systemic therapy achieved long-term survival or even cure in about one quarter of the patients. Evidence is mostly based on the common cancer sites: lung, colorectal and prostate cancers. It has however been proposed that this intermediate oligometastatic cancer stage may also exist in other cancer types, opening a curative window for many more cancer patients.
The 1945-OligoRare is an academic clinical study led by the EORTC in 6 countries in Europe (BE,CH,IT,DE,FR,UK) with a transatlantic collaboration with British Columbia Cancer Agency in Canada. It will be the first study to use the stereotactic body radiotherapy -SBRT- approach (targeted radiotherapy) in cancers where the oligometastatic state is uncommon, thus where data is severely lacking. Patients with oligometastatic cancer, including all solid cancer types except lung, breast, colon and prostate cancer will be eligible. 
Its primary objective is to assess if the addition of SBRT improves the overall survival compared to the standard of care treatment alone, in eligible patients with a maximum of 5 oligometastatic lesions. A total of 200 patients will be recruited over a period of 5.5 years.

Further information can be found here

icon-social-share-linkedin Created with Sketch.
icon-play Created with Sketch.
icon-download Created with Sketch.